Antihemophilic viii/vwf comp
Products billed under this code include Alphanate.
Payment limit per PER FACTOR VIII IU, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Alphanate.
Payment limit per PER FACTOR VIII IU, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Alphanate | Grifols USA, LLC | 68516-4616-01 | 1 | $1.267 |
| Alphanate | Grifols USA, LLC | 68516-4617-01 | 1 | $1.267 |
| Alphanate | Grifols USA, LLC | 68516-4618-02 | 1 | $1.267 |
| Alphanate | Grifols USA, LLC | 68516-4619-02 | 1 | $1.267 |
| Alphanate | Grifols USA, LLC | 68516-4620-02 | 1 | $1.267 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.267 | −$0.002 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted September 17, 2026 |
| 3Q26 | $1.269 | +$0.017 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted September 15, 2026 |
| 2Q26 | $1.252 | +$0.011 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted September 15, 2026 |
| 1Q26 | $1.241 | −$0.004 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted September 15, 2026 |
| 4Q25 | $1.245 | +$0.018 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted September 8, 2026 |
| 3Q25 | $1.227 | +$0.029 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted March 10, 2026 |
| 2Q25 | $1.198 | −$0.001 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted March 10, 2026 |
| 1Q25 | $1.199 | −$0.026 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted December 19, 2025 |
| 4Q24 | $1.225 | +$0.035 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 11, 2025 |
| 3Q24 | $1.19 | +$0.004 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 11, 2025 |
| 2Q24 | $1.186 | −$0.016 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted March 11, 2025 |
| 1Q24 | $1.202 | −$0.016 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted December 19, 2024 |
| 4Q23 | $1.218 | +$0.002 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted October 10, 2024 |
| 3Q23 | $1.216 | +$0.045 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 5, 2024 |
| 2Q23 | $1.171 | +$0.008 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted February 23, 2024 |
| 1Q23 | $1.163 | +$0.015 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted December 6, 2023 |
| 4Q22 | $1.148 | +$0.008 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 22, 2023 |
| 3Q22 | $1.14 | −$0.011 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 9, 2023 |
| 2Q22 | $1.151 | +$0.019 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted December 14, 2022 |
| 1Q22 | $1.132 | −$0.003 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 8, 2022 |
| 4Q21 | $1.135 | +$0.014 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 2, 2022 |
| 3Q21 | $1.121 | +$0.005 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted June 2, 2022 |
| 2Q21 | $1.116 | −$0.007 | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted March 1, 2022 |
| 1Q21 | $1.123 | – | PER FACTOR VIII IU | Antihemophilic viii/vwf comp | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.